Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) CAO Sells $11,160.60 in Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RAREGet Rating) CAO Theodore Alan Huizenga sold 132 shares of the business’s stock in a transaction dated Saturday, April 16th. The stock was sold at an average price of $84.55, for a total transaction of $11,160.60. Following the completion of the sale, the chief accounting officer now directly owns 16,914 shares of the company’s stock, valued at approximately $1,430,078.70. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

RARE stock traded up $1.17 on Tuesday, hitting $79.61. 3,980 shares of the company’s stock traded hands, compared to its average volume of 437,963. Ultragenyx Pharmaceutical Inc. has a 1-year low of $61.21 and a 1-year high of $119.54. The firm has a market cap of $5.52 billion, a PE ratio of -11.69 and a beta of 1.68. The stock’s fifty day moving average is $71.42.

Ultragenyx Pharmaceutical (NASDAQ:RAREGet Rating) last issued its quarterly earnings results on Thursday, February 10th. The biopharmaceutical company reported ($1.79) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.32) by ($0.47). The firm had revenue of $83.39 million during the quarter, compared to analysts’ expectations of $83.68 million. Ultragenyx Pharmaceutical had a negative net margin of 129.20% and a negative return on equity of 44.24%. The firm’s revenue was down 8.9% compared to the same quarter last year. During the same quarter last year, the company posted ($1.34) EPS. Equities analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.57 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of RARE. Benjamin F. Edwards & Company Inc. purchased a new stake in shares of Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $66,000. Alpha Paradigm Partners LLC acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $113,000. Advisor Group Holdings Inc. increased its stake in Ultragenyx Pharmaceutical by 26.6% in the 3rd quarter. Advisor Group Holdings Inc. now owns 1,612 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 339 shares during the period. Trek Financial LLC acquired a new position in Ultragenyx Pharmaceutical in the 4th quarter valued at approximately $205,000. Finally, Allspring Global Investments Holdings LLC acquired a new position in shares of Ultragenyx Pharmaceutical during the 4th quarter worth $207,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

RARE has been the subject of a number of recent research reports. StockNews.com initiated coverage on shares of Ultragenyx Pharmaceutical in a research report on Thursday, March 31st. They set a “hold” rating for the company. JPMorgan Chase & Co. upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “overweight” rating and set a $132.00 target price for the company in a research report on Friday, February 11th. Zacks Investment Research upgraded shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating and set a $75.00 target price for the company in a research report on Tuesday, February 15th. Morgan Stanley decreased their target price on shares of Ultragenyx Pharmaceutical from $120.00 to $118.00 and set an “overweight” rating for the company in a research report on Friday, February 11th. Finally, Credit Suisse Group upgraded shares of Ultragenyx Pharmaceutical from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $99.00 to $105.00 in a research report on Wednesday, March 16th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Buy” and a consensus target price of $122.27.

Ultragenyx Pharmaceutical Company Profile (Get Rating)

Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII.

Featured Articles

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.